Physician profile
Ava C Rosenberg
NPI 1073692125
$3,877.43
in general payments reported to CMS, 2019-2025
25 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.33 · 2020: $536 · 2021: $1,062 · 2022: $538 · 2023: $379 · 2024: $673 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.76 | 2021-2024 | Vraylar, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $435.75 | 2020-2021 | |
| Pfizer INC. | $429.61 | 2019-2025 | |
| Lilly USA, LLC | $401.34 | 2020-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $256.93 | 2020-2021 | |
| Exact Sciences Corporation | $255.09 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $254.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.69 | 2020-2022 | |
| Amgen INC. | $164.44 | 2020-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $157.80 | 2022-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company Ltd. | $152.13 | 2022 | |
| Allergan, INC. | $131.50 | 2020-2021 | |
| Novo Nordisk INC | $106.77 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $86.61 | 2024-2025 | Veozah |
| Almatica Pharma LLC | $55.57 | 2022-2023 | Sertraline Hcl, Loreev Xr, Gralise |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46.38 | 2024-2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $26.32 | 2025 | Neffy |
| Mayne Pharma Commercial LLC | $24.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.80 | 2020 | |
| Horizon Therapeutics Plc | $22.36 | 2020 | |
| Merck Sharp & Dohme LLC | $21.40 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2019 | |
| Sanofi Pasteur INC. | $17.77 | 2023 | |
| Amag Pharmaceuticals, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ava Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.